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ONE-SENTENCE SUMMARY
MTBP suppresses HCC migration by inhibiting the Erk1/2-Elk-1 signaling via 
competitive binding with an Erk1/2-tranporter, IPO7.
ABSTRACT
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, 
and the prognosis of HCC patients, especially those with metastasis, remains extremely 
poor. This is partly due to unclear molecular mechanisms underlying HCC metastasis. 
Our previous study indicates that MDM2 Binding Protein (MTBP) suppresses migration 
and metastasis of HCC cells. However, signaling pathways regulated by MTBP remain 
unknown. To identify metastasis-associated signaling pathways governed by MTBP, 
we have performed unbiased luciferase reporter-based signal array analyses and 
found that MTBP suppresses the activity of the ETS-domain transcription factor Elk-1, 
a downstream target of Erk1/2 MAP kinases. MTBP also inhibits phosphorylation of 
Elk-1 and decreases mRNA expression of Elk-1 target genes. Reduced Elk-1 activity is 
caused by inhibited nuclear translocation of phosphorylated Erk1/2 (p-Erk) by MTBP 
and subsequent inhibition of Elk-1 phosphorylation. We also reveal that MTBP inhibits 
the interaction of p-Erk with importin-7/RanBP7 (IPO7), an importin family member 
which shuttles p-Erk into the nucleus, by binding to IPO7. Moreover, high levels of 
MTBP in human HCC tissues are correlated with cytoplasmic localization of p-Erk1/2. 
Our study suggests that MTBP suppresses metastasis, at least partially, by down-
modulating the Erk1/2-Elk-1 signaling pathway, thus identifying a novel regulatory 
mechanism of HCC metastasis by regulating the subcellular localization of p-Erk.
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INTRODUCTION
Metastasis is the primary cause of the poor 
prognosis in cancer patients, being responsible for about 
90% of deaths of patient with solid tumors [1]. Migration 
of cancer cells to distant sites in the body is one of the 
critical steps for metastasis [2]. Identifying the molecular 
mechanisms of cancer cell migration and metastasis will 
significantly help in improvement of prognosis of cancer 
patients.
Hepatocellular carcinoma (HCC) is the third most 
common cause of cancer-related death and stands fifth 
in ranking of most common cancer worldwide. The 
5-year survival rate is extremely poor despite surgical 
resection. This is mainly due to microvascular invasion 
and extrahepatic metastasis to lymph nodes, lungs, and 
bones [3, 4]. Hence, identifying and characterizing critical 
molecular mediators of metastasis suppression would lead 
to therapeutic intervention in HCC precision therapy.
MDM2 Binding Protein (MTBP) was initially 
identified as a protein that interacted with the 
oncoprotein Mouse Double Minute 2 homolog (MDM2) 
[5]. Increasing evidence suggests that MTBP inhibits 
cancer cell migration and metastasis independent of the 
MDM2-p53 pathway, since MTBP knockdown increases 
migration of cells lacking both p53 and MDM2 [6, 7]. 
In head and neck carcinoma, reduced MTBP expression 
in tumors is correlated with reduced patient survival [8]. 
We have previously reported that MTBP expression is 
reduced in HCC tissues while overexpression of MTBP 
inhibits cancer cell migration in osteosarcoma and HCC 
in a p53-independent manner in culture and in mouse 
models [7, 9]. On the other hand, there are a few reports 
suggesting cancer-promoting roles of MTBP in leukemia 
and breast cancer by cooperating with Myc [10-12]. 
Thus, the role of MTBP in cancer progression appears to 
be dependent on cellular context [6]. Additionally, other 
functions of MTBP have been reported; these include 
its roles in chromosome segregation [13] and DNA 
replication origin firing [14].
Our recent study suggests that MTBP suppresses 
migration of HCC cells, at least partially, by inhibiting 
the actin-crosslinking function of α-actinin-4 (ACTN4) 
[9]. However, the mechanism behind MTBP-mediated 
suppression of HCC migration other than ACTN4 
inhibition remains unknown. Toward this goal 
and to understand signaling pathways involved in 
MTBP-mediated migration suppression in HCC, we 
performed an unbiased screening using a luciferase-
based signal array with two HCC cell lines, leading to 
identification of MTBP as a negative regulator of the 
Erk1/2-Elk-1 signaling pathway. This effect of MTBP 
was indirectly caused by its inhibitory interaction with 
importin-7/RanBP7 (IPO7), a key protein that imports 
phosphorylated Erk1/2 (p-Erk) from the cytoplasm to the 
nucleus.
RESULTS
MTBP inhibits Elk-1 activity
To understand the molecular basis of the biological 
function of MTBP and determine signaling pathways 
regulated by MTBP, we performed unbiased signal 
array analyses using the luciferase reporter-based Cignal 
Finder Reporter Arrays (SA Biosciences). This assay 
allows measuring activities of 45 transcription factors 
associated with specific signaling pathways. Since 
MTBP’s effects on cancer cell migration is independent of 
the MDM2-p53 pathway [6, 7], we performed luciferase 
assays using mutant p53-carrying HCC cells lines, PLC/
PRF/5 (p53R249S) and Huh7 (p53Y220C), and the results were 
compared between control cells and those overexpressing 
MTBP. In both cell lines tested, the activity of an ETS-
domain transcription factor Elk-1 was consistently 
suppressed by MTBP overexpression up to ~45% when 
compared to controls (Figure 1A and Supplementary 
Figure 1A). AP-1 and EGR1 transcriptional activities were 
also suppressed by MTBP to a lesser extent. Since both 
transcription factors are downstream targets of Elk-1, this 
could be due to reduced Elk-1 activity [15, 16]. In contrast 
with previous reports using lymphoma or MCF7 cells 
[10, 17], activity of c-Myc was not significantly altered 
by MTBP in PLC/PRF/5 and Huh7 cells (Figure 1A and 
Supplementary Figure 1A). This divergence may be due to 
the differences in tissue types or cellular contexts.
Elk-1 is phosphorylated and activated as a 
transcription factor following treatment with several 
growth factors, such as EGF [18]. To validate inhibition 
of Elk-1 activity by MTBP, we performed quantitative RT-
PCR (qRT-PCR) to measure mRNA expression of three 
Elk-1 target genes, EGR-1, c-fos, and PKCα, using PLC/
PRF/5 and Huh7 cell lines with or without overexpression 
of MTBP, in the absence or presence of EGF stimulation 
[18]. In agreement with signal array analyses, MTBP 
overexpression significantly suppressed mRNA induction 
of all the tested Elk-1 target genes by EGF (Figure 1B and 
Supplementary Figure 1B).
To further confirm that MTBP inhibited activation of 
Elk-1, phosphorylation status of Elk-1 was examined using 
cytoplasmic and nuclear protein extracts. EGF treatment 
increased phosphorylation of Elk-1 in the nucleus which 
was significantly inhibited by MTBP overexpression 
in both PLC/PRF/5 and Huh7 cells (Figure 1C  
and Supplementary Figure 1C). These results suggest that 
MTBP suppresses Elk-1 transcriptional activity through 
inhibition of Elk-1 phosphorylation.
MTBP inhibits nuclear translocation of 
phosphorylated Erk1/2
Phosphorylation of Elk-1 in the nucleus is 
mediated by phosphorylated Erk1/2 MAP kinase 
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(p-Erk), leading to transactivation of downstream 
target genes involved in cell migration and metastasis 
[18-21]. Hence, we investigated whether MTBP 
could modulate the activity of Erk1/2 by examining 
phosphorylation status and subcellular localization 
of Erk1/2. Results from western blotting showed that 
MTBP overexpression caused increase (approximately 
2- to 3-fold) in the cytoplasmic p-Erk with decrease 
Figure 1: MTBP inhibits Elk-1 activity. (A) Luciferase-based signal array analysis using PLC/PRF/5 cells infected with lentiviral 
vectors encoding empty (control) or MTBP cDNA. Results showing fold change of the luciferase activity altered by MTBP overexpression, 
compared to the control lentiviral vector (set as 1) of 45 genes related with different signaling pathways. An arrow indicates that Elk-
1 activity was significantly suppressed by MTBP overexpression. Ud., undetectable. Error bars: mean ± S.D. from three independent 
experiments. Student’s t test: *, P < 0.05 and **, P < 0.01. Other pathways had no statistical significance. (B) Results of qRT-PCR to measure 
mRNA expression of EGR1, c-fos, and PKCα using PLC/PRF/5 cells infected with lentiviral vectors encoding empty (control, grey) or 
MTBP cDNA (black), with (+) or without (-) 50 ng/ml of EGF stimulation for 15 min. Data are normalized by values of GAPDH mRNA. 
Error bars: means ± S.D. from three independent experiments. Student’s t test: *, P < 0.05 and **, P < 0.01. NS, not significant at a 0.05 
significance level. (C) Western blotting for MTBP, phosphorylated Elk-1 at serine 383 (p-Elk-1), total Elk-1, Lamin B, and GAPDH using 
cytoplasmic and nuclear protein extracts from PLC/PRF/5 cells treated with solvent (-) or 50 ng/ml of EGF (+) for 30 min.
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(approximately 2- to 4-fold) in the nuclear p-Erk when 
compared to the controls, especially upon EGF treatment, 
suggesting inhibition of p-Erk nuclear import by MTBP 
(Figure 2A and 2B). Notably, overall cellular amount 
(nucleus plus cytoplasm) of p-Erk was similar between 
control and MTBP-overexpressing cells (Figure 2A  
and 2B). Immunofluorescence studies also revealed that 
EGF-induced nuclear import of p-Erk was inhibited in 
both PLC/PRF/5 and Huh7 cells overexpressing MTBP 
when compared with control cells (Figure 2C and 2D). 
These results suggest that MTBP inhibits Elk-1 activity 
mainly by preventing nuclear translocation of p-Erk, rather 
than altering phosphorylation status of Erk1/2.
MTBP is shown to alter cancer cell migration and 
metastasis regardless of p53 status. Since we used HCC 
cells with p53 mutations, we additionally examined 
whether MTBP altered nuclear translocation of p-Erk 
upon EGF stimulation in HepG2 cells expressing wild-
type p53. As expected, MTBP overexpression still 
inhibited nuclear translocation of p-Erk in HepG2 cells 
(Supplementary Figure 2A and 2B). We furthermore 
assessed whether MTBP inhibited mRNA expression of 
Elk-1 target genes (EGR-1, c-fos, PKCα) in HepG2 cells. 
Consistently, MTBP overexpression suppressed EGF-
mediated increase in mRNA expression of Elk-1 target 
genes, as well as their basal expression levels without EGF 
treatment (Supplementary Figure 2C). Together, these 
results strongly suggest that MTBP inhibits the Erk1/2-
Elk-1 signaling regardless of the p53 status.
MTBP inhibits HCC cell migration through 
suppressing the Erk1/2-Elk-1 axis
Next, we wanted to examine the functional 
association between MTBP and the Erk1/2-Elk-1 axis 
on HCC cell migration using transwell migration assays. 
First, MTBP overexpression or knockdown of Erk1/2 
significantly reduced migratory potential of both PLC/
PRF/5 and Huh7 cells (Figure 3A and western blotting 
results in Supplementary Figure 3A). Concomitant 
overexpression of MTBP in Erk1/2-knockdown cells 
resulted in further reduction in migration of Huh7 cells, 
but there was no significant reduction in PLC/PRF/5 cells 
(Figure 3A and western blotting results in Supplementary 
Figure 3A). Since our previous study shows that migration 
of Huh7 cells is partially dependent on ACTN4, but 
migration of PLC/PRF/5 cells is ACTN4-independent [9], 
these data may suggest that migratory potential of PLC/
PRF/5 is mainly dependent on the Erk1/2-Elk-1 axis.
We next examined functional association between 
MTBP and Elk-1. Increased migration by MTBP 
knockdown was attenuated by concomitant knockdown of 
Elk-1 in both PLC/PRF/5 and Huh7 cell lines (Figure 3B  
and western blotting results in Supplementary Figure 3B). 
Also, overexpression of Elk-1 in PLC/PRF/5 cells increased 
the migration, which was nullified by concomitant 
overexpression of MTBP (Figure 3C and western 
blotting results in Supplementary Figure 3C). Moreover, 
overexpression of MTBP in Elk-1-knockdown cells failed 
to further reduce migration of PLC/PRF/5 cells in the 
presence of EGF (Figure 3D and western blotting results 
in Supplementary Figure 3D). These results suggest that 
migration suppression by MTBP in PLC/PRF/5 cells is 
mainly dependent on the Erk1/2-Elk-1 axis. On the other 
hand, overexpression of MTBP in Elk-1-knockdown Huh7 
cells still reduced cell migration (Supplementary Figure 3D 
and 3E). These results support the idea that MTBP inhibits 
migration of Huh7 cells in Erk1/2-Elk-1 axis–dependent 
and –independent manners.
We also examined whether MTBP could inhibit 
migration of wild-type p53-expressing HepG2 cells 
via Elk-1. As expected, MTBP knockdown increased 
migration of HepG2 cells, which was significantly 
attenuated by concomitant knockdown of Elk-1 
(Supplementary Figure 4A and 4B). Additionally, we 
tested whether mutant p53 was involved in the MTBP-
mediated inhibition of Elk-1 and HCC cell migration, 
using Huh7 cells down-modulated for mutant p53. 
Although knockdown of mutant p53 decreased migration 
of Huh7 cells, knockdown of MTBP in mutant p53-
knockdown Huh7 cells still increased the migration, 
which was significantly attenuated by simultaneous 
knockdown of Elk-1 (Supplementary Figure 4C and 4D). 
Thus, MTBP inhibits HCC cell migration, at least partially, 
by inhibiting Elk-1 activity, regardless of the p53 status.
MTBP inhibits interactions between p-Erk and 
IPO7 by binding to IPO7
Neither Erk1 nor Erk2 has a nuclear localization 
signal (NLS) [22, 23], while importin 7 (IPO7) is 
the major player that shuttles p-Erk into the nucleus 
[24, 25]. We therefore examined the effects of MTBP 
overexpression on the interactions between p-Erk and 
IPO7 by co-immunoprecipitation studies using both PLC/
PRF/5 and Huh7 cells. In both cell lines, overexpression 
of MTBP inhibited the endogenous interaction between 
p-Erk and IPO7 (Figure 4A and 4B; lane 3 vs lane 7 for 
IPO7 blots, lane 4 and lane 8 for p-Erk blots).
To determine whether MTBP could endogenously 
interact with p-Erk and/or IPO7, co-immunoprecipitation 
studies were performed using protein extracts from PLC/
PRF/5 and Huh7 cells. Endogenous interactions between 
MTBP and IPO7 were detected in both cell lines (Figure 4C 
and 4D). However, we failed to observe the MTBP-p-
Erk interaction in both cell lines (Supplementary Figure 
5). These results propose that MTBP competitively binds 
with IPO7 to inhibit the p-Erk-IPO7 interaction, leading to 
cytoplasmic retention of p-Erk and hence attenuated Elk-1 
phosphorylation and activity.
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C-terminal region of MTBP is required for 
binding to IPO7 and inhibiting p-Erk nuclear 
translocation
Next, we attempted to identify a region required 
for the MTBP-IPO7 interaction. We previously generated 
a series of N-terminal FLAG-tagged deletion/mutation 
constructs for MTBP, including full-length MTBP (MTBP), 
N-terminal region deleted mutant (F4-MTBP), and 
C-terminal region deleted mutant (ΔC-MTBP, Figure 5A) 
[7]. We overexpressed these FLAG-tagged MTBP in Huh7 
cells and performed co-immunoprecipitation studies with 
FLAG- and IPO7-specific antibodies. We found that full-
length and F4-MTBP interacted with endogenous IPO7, 
Figure 2: MTBP inhibits nuclear translocation of phosphorylated Erk1/2. (A and B) Western blotting for Erk1/2 and 
phosphorylated Erk1/2 at Thr202/Tyr204 (p-Erk) using cytoplasmic and nuclear protein extracts from PLC/PRF/5 (A) and Huh7 (B) cells 
treated with solvent (-) or 50 ng/ml of EGF (+) for 30 min. By setting the control cytoplasmic fraction and the control nuclear fraction as 
1, the relative ratios for p-Erk/total Erk to the control fractions are shown below p-Erk blots. (C and D) Immunofluorescence studies for 
DAPI (blue), MTBP (red), and p-Erk (green) following treatment of control or MTBP-overexpressing cells with (+) or without (-) 50 ng/
ml of EGF treatment for 30 min in PLC/PRF/5 (C) and Huh7 (D) cells. Merged images for DAPI, MTBP, and p-Erk are also shown on the 
right. Scale bar, 25 μm.
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but ΔC-MTBP failed to bind with IPO7 (Figure 5B). 
Thus, the C-terminal region spanning from amino acids 
760 to 904 of MTBP was required for the MTBP-IPO7 
interaction (Figure 5B).
We also examined whether the ΔC-MTBP retained the 
ability to inhibit the Erk1/2-Elk-1 signaling. As expected, 
overexpression of ΔC-MTBP which could not bind to IPO7 
failed to inhibit nuclear translocation of p-Erk, following 
EGF stimulation in PLC/PRF/5 cells (Figure 5C). Also, 
qRT-PCR assays to measure mRNA expression of the Elk-
1 target genes, EGR-1, c-fos, and PKCα revealed that ΔC-
MTBP lost the ability to suppress mRNA expression of Elk-
1 downstream targets, unlike the case of full-length MTBP 
(Figure 5D, compare the result with Figure 1A) in both 
PLC/PRF/5 and Huh7 cells. Moreover, unlike full-length 
MTBP, overexpression of ΔC-MTBP failed to reduce the 
migration of both PLC/PRF/5 and Huh7 cells (Figure 5E). 
These results suggest that the C-terminal region of MTBP 
Figure 3: MTBP inhibits HCC cell migration through suppressing the Erk1/2-Elk-1 axis. (A) Transwell migration assays using 
PLC/PRF/5 (left) and Huh7 (right) cells downregulated for Erk1/2 with or without overexpression of MTBP. Cells infected with lentiviral 
vectors encoding a non-target shRNA (control) or shRNAs for Erk1 and Erk2 (Erk1/2) were further infected with a lentiviral vector encoding 
MTBP cDNA (MTBP). Cells were plated on the upper chambers of the transwell, and migrating cells in the entire fields were counted 12 hours 
later. (B) Transwell migration assays using PLC/PRF/5 (left) and Huh7 (right) cells knockdown for Elk-1 (Elk-1) and/or MTBP (MTBP). (C) 
Transwell migration assays using PLC/PRF/5 cells infected with lentiviral vectors encoding empty (control) or Elk-1 cDNA (Elk-1) with or 
without concomitant overexpression of MTBP. (D) Transwell migration assays using PLC/PRF/5 cells infected with lentiviral vectors encoding 
non-target (control) or Elk-1 shRNAs with or without concomitant overexpression of MTBP, in the presence of EGF (100 ng/ml). Graphs 
showing relative cell migration (%) compared to the number of migrating cells in control. Representative images below the graphs. Error bars: 
means ± S.D. from three independent experiments. Student’s t test: **, P < 0.01. NS, not significant. Scale bar, 25 μm.
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is required for binding to IPO7, inhibiting the Erk1/2-Elk-1 
signaling, and suppressing HCC migration.
Cytoplasmic MTBP plays a role in inhibiting the 
Erk1/2-Elk-1 signaling
MTBP is present in both the cytoplasm and 
nucleus [7]. We therefore wanted to examine whether 
the cytoplasmic portion of MTBP played a role in 
inhibiting IPO7’s ability to import p-Erk to the nucleus. 
MTBP possesses a NLS which is required for MTBP 
protein to be imported into the nucleus (Figure 5A). 
First, we confirmed that a mutant MTBP with disruption 
of the NLS (MTBPNLS) [7] retained the ability to 
bind with IPO7 in PLC/PRF/5 and Huh7 cells by co-
immunoprecipitation studies for FLAG-tagged MTBPNLS 
and IPO7 (Figure 6A and Supplementary Figure 6A). 
Next, we performed immunofluorescence studies for 
p-Erk using both PLC/PRF/5 and Huh7 cells with or 
without overexpression of FLAG-tagged MTBPNLS and 
in the absence or presence of EGF stimulation. In both 
cell lines, MTBPNLS still inhibited the nuclear translocation 
of p-Erk following EGF stimulation (Figure 6B). Also, 
we examined whether MTBPNLS retained the ability 
to suppress Elk-1 activity by measuring transcription 
of Elk-1 target genes in both PLC/PRF/5 and Huh7 
cells (Figure 6C). As expected, MTBPNLS inhibited 
mRNA expression of Elk-1 downstream targets with or 
without EGF stimulation, as in the case of full-length 
MTBP (Figure 6C, compare the result with Figure 1B). 
Moreover, overexpression of MTBPNLS reduced the 
migration of PLC/PRF/5 and Huh7 cells (Figure 6D and 
Supplementary Figure 6B). These results suggest that 
the cytoplasmic portion of MTBP plays a crucial role in 
inhibiting the Erk1/2-Elk-1 signaling and migration.
High MTBP levels are correlated with 
cytoplasmic p-Erk in human HCC tissues
Our tissue culture experiments indicate that 
MTBP negatively regulates nuclear import of p-Erk. To 
investigate correlation between MTBP levels and p-Erk 
subcellular localization in human HCC tissues, we 
performed immunohistochemistry (IHC) for MTBP and 
p-Erk using paraffin embedded non-tumor liver and HCC 
tissues, comprising 10 non-tumor liver, 57 primary HCC, 
and 36 metastatic HCC tissues. MTBP was diffusively 
located to both the cytoplasm and the nucleus in non-tumor 
liver and HCC tissues, while the staining patterns of p-Erk 
were diverse where some were localized to the nucleus 
and others were mainly in the cytoplasm (Figure 7A). 
Consistent with our previous report [9], overall MTBP 
Figure 4: MTBP inhibits interactions between p-Erk and IPO7 by binding to IPO7.  (A and B) Co-immunoprecipitation (IP) 
studies for endogenous p-Erk and IPO7 using protein extracts (~200 μg) from PLC/PRF/5 (A) and Huh7 (B) cells infected with lentiviral 
vectors encoding empty (control) or MTBP cDNA (MTBP). Isotypes were used as negative controls (m: mouse, r: rabbit). (C and D) Co-
immunoprecipitation studies for endogenous MTBP and IPO7 using PLC/PRF/5 (C) and Huh7 (D) cells. Isotypes were used as negative 
controls (m: mouse, g: goat). 10% of the total amount of protein lysate (~20 μg) was used for input.
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levels were significantly lower in both primary and 
metastatic HCC tumors when compared with non-tumor 
liver tissues, although there were some HCC tissues 
showing moderately high levels of MTBP (Figure 7B). 
Interestingly, MTBP levels in HCC at metastatic sites were 
significantly lower than those at primary sites (Figure 7B).
To test the hypothesis that high levels of MTBP 
are associated with increased cytoplasmic p-Erk in HCC 
tissues, we scored subcellular localization of p-Erk as 
cytoplasm (C)>nucleus (N) vs C≤N, along with MTBP 
expression levels which were categorized as low (<3) vs 
high (≥3) scores, using both primary and metastatic HCC 
Figure 5: C-terminal region of MTBP is required for binding to IPO7 and inhibiting p-Erk nuclear translocation. (A) 
Deletion constructs of MTBP tagged with the FLAG peptide at the N-terminus. MTBP: full-length MTBP; F4-MTBP (F4): N-terminal 
region deleted MTBP; ΔC-MTBP (ΔC): C-terminal region deleted MTBP. Numbers indicate amino acid of MTBP. Black bars indicate a 
nuclear localization signal (NLS) spanning between codons 730 and 753. (B) Co-immunoprecipitation (IP) studies between MTBP (FLAG 
tag) and IPO7 using protein extracts (~200 μg) from Huh7 cells expressing full-length MTBP (MTBP), F4-MTBP (F4), and ΔC-MTBP 
(ΔC). Isotypes were used as negative controls (m: mouse). 10% of the total amount of protein lysate (~20 μg) was used for input. (C) 
Immunofluorescence studies for p-Erk following treatment with solvent (EGF-) or 50 ng/ml of EGF for 30 min using PLC/PRF/5 cells 
with (ΔC) or without (control) overexpression of ΔC-MTBP. Scale bar, 50 μm. (D) Results of qRT-PCR to measure mRNA expression of 
EGR1, c-fos, and PKCα using PLC/PRF/5 (top) and Huh7 (bottom) cells infected with lentiviral vectors encoding empty (control, grey) or 
ΔC-MTBP cDNA (ΔC, black), with (+) or without (-) 50 ng/ml of EGF stimulation for 15 min. Data are normalized by values of GAPDH 
mRNA. Error bars: means ± S.D. from three independent experiments. Student’s t test. NS, not significant. (E) Transwell migration assays 
for 12 hours using PLC/PRF/5 (left) and Huh7 (right) cells infected with lentiviral vectors encoding empty (control) and ΔC-MTBP cDNA 
(ΔC). Error bars: means ± S.D. from three independent experiments. Student’s t test. NS, not significant.
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tissues. Interestingly, there was a significant association 
between high expression of MTBP and cytoplasmic 
localization of p-Erk after controlling for tumor location 
(Figure 7A, 7C, and Supplementary Table 1; p-value 
from exact logistic regression=0.034). We could not 
detect significant association of levels of MTBP or p-Erk 
with tumor size or pathological grade of primary HCC 
(Supplementary Table 2). These results support our tissue 
culture data showing that MTBP inhibits nuclear import 
of p-Erk1/2.
Sorafenib is a multikinase inhibitor that is shown 
to improve survival in patients with advanced HCC 
and inhibit migration of HCC cells [26, 27]. Hence, 
we examined the possible cooperative effects between 
sorafenib and MTBP overexpression on HCC migration. 
We chose 5 μM of sorafenib which had little effects on 
Figure 6: Cytoplasmic MTBP plays a role in inhibiting the Erk1/2-Elk-1 signaling. (A) Co-immunoprecipitation studies 
between a NLS mutant MTBP (MTBPNLS) and IPO7 using protein lysates (~200 μg) from PLC/PRF/5 cells expressing FLAG-tagged 
MTBPNLS. MTBPNLS was precipitated using anti-FLAG M2 affinity gel. Isotypes and protein A/G agarose beads were used as negative 
controls. 10% of the total amount of protein lysate (~20 μg) was used for input. (B) Immunofluorescence studies for p-Erk following 
treatment with solvent (EGF-) or 50 ng/ml of EGF for 30 min using PLC/PRF/5 (left) and Huh7 (right) cells with (MTBPNLS) or without 
(control) overexpression of MTBPNLS. Scale bar, 25 μm. (C) Results of qRT-PCR to measure EGR1, c-fos, and PKCα mRNA expression 
using PLC/PRF/5 (top) and Huh7 (bottom) cells infected with lentiviral vectors encoding empty (control, grey) or MTBPNLS cDNA (NLS, 
black), with (+) or without (-) 50 ng/ml of EGF stimulation for 15 min. Data are normalized by values of GAPDH mRNA. Error bars: 
means ± S.D. from three independent experiments. *, P < 0.05 and **, P < 0.01; Student’s t test. NS, not significant. (D) Transwell migration 
assays for 12 hours using PLC/PRF/5 cells infected with lentiviral vectors encoding empty (control) or FLAG-tagged MTBPNLS. Graphs 
showing relative cell migration (%) compared to the number of migrating cells in control. Error bars: means ± S.D. from three independent 
experiments. *, P < 0.05; Student’s t test.
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viability of both PLC/PRF/5 and Huh7 cells following 24 
hours of treatment (Supplementary Figure 7A). Although 
sorafenib alone inhibited migration of PLC/PRF/5 and 
Huh7 cells, the inhibitory effects of sorafenib on the 
migration of MTBP-overexpressing cells were subtle 
without statistical significance (Supplementary Figure 7B). 
Thus, we could not detect obvious cooperative effects 
between sorafenib and MTBP overexpression in the 
experimental condition we used. These results further 
support our findings that sorafenib and MTBP, both 
commonly inhibit the Erk pathway but each has non-
overlapping effects on cancer cell migration [7, 26].
Figure 7: High MTBP levels are correlated with cytoplasmic p-Erk in human HCC tissues. (A) Representative images of 
IHC for MTBP and p-Erk using human non-tumor liver tissues (n=10), primary HCC (n= 57), and metastatic HCC (n= 36) tissues. MTBP 
high: score≥3, MTBP low: score<3. Scale bar, 25 μm. (B) Summary of IHC for MTBP. Graph showing MTBP expression (immunoreactive) 
scores in non-tumor liver, primary HCC, and metastatic HCC tissues. Mann-Whitney test: **, P < 0.01. (C) Summary of association between 
MTBP levels and subcellular localization of p-Erk in human HCC tissues (combining primary and metastatic tissues). Graph showing % 
of tumors with different cellular distributions of p-Erk by expression scores of MTBP (<3 vs ≥3). Exact logistic regression controlling for 
tumor location: *, P < 0.05. (D) Proposed model for MTBP-mediated inhibition of the Erk1/2-Elk-1 signaling pathway. MTBP inhibits 
binding of p-Erk with IPO7, which reduces nuclear import of p-Erk, leading to decrease in Elk-1 phosphorylation and Elk-1 downstream 
target gene expression (EGR1, c-fos, PKCα).
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DISCUSSION
In this study, we have found that high MTBP 
expression in HCC cells and tissues are associated with 
increased cytoplasmic localization of p-Erk. This is 
caused by competitive binding of MTBP to IPO7, a p-Erk 
nuclear transporter. As a result, MTBP inhibits the p-Erk’s 
ability to phosphorylate and activate Elk-1 transcription 
factor, leading to inhibition of HCC migration (Figure 
7D). Activation of the MAPK/Erk signaling pathway is 
well characterized for regulation of HCC progression and 
metastasis via multiple molecular machineries [28-30]. 
Thus, our study has revealed a novel mechanism behind 
HCC migration and metastasis through the MTBP-IPO7-
Erk1/2-Elk-1 axis and suggests that reduced MTBP could 
serve as a novel biomarker of HCC metastasis.
Due to lack of NLS in Erk1/2 and their molecular 
sizes (42 and 44 kDa), Erk1/2 was originally believed to 
be passively imported into the nucleus. Several specialized 
anchor/scaffold proteins that retain p-Erk in the cytoplasm 
have also been found [22]. Recent studies have identified 
IPO7 as a protein that actively binds to and imports 
p-Erk1/2 into the nucleus [24, 25]. Our results indicate 
that MTBP is a novel player that inhibits the p-Erk-IPO7 
interaction as well as nuclear translocation of p-Erk. 
However, it is still unclear whether MTBP directly binds 
to IPO7 or if another protein mediates the MTBP-IPO7 
interaction in cells.
Erk1/2 plays crucial roles in not only Elk-1 
phosphorylation, but also mitochondrial biogenesis, 
Golgi fragmentation, and cytoskeletal reorganization 
[31]. Further studies are required to determine whether 
MTBP has any impact on these Erk1/2 functions. On the 
other hand, MTBP has also been reported to regulate other 
biological functions including replication origin firing 
[14], mitotic checkpoint [13], and c-Myc activity [10, 11]. 
It would be important to investigate potential involvement 
of Erk1/2 and IPO7 in these biological phenotypes 
regulated by MTBP and also determine whether or not 
MTBP regulates the nuclear translocation of some of the 
key factors involved in these cellular activities.
Elk-1 regulates migration of multiple cancer types 
through its downstream targets including c-fos, EGR1, 
and PKCα [32-34]. Specifically, PKCα is shown to be 
associated with HCC cell migration and invasion and is 
highly expressed in the poorly-differentiated human HCC 
cells [32, 35]. Also, both c-fos and EGR1 are implicated 
in promoting HCC migration and progression [36, 37]. 
Hence, it would be tempting to identify a novel and critical 
Elk-1 target that regulates HCC metastasis and to examine 
whether MTBP suppresses its expression.
Although MTBP has a NLS and is located to both 
the cytoplasm and the nucleus [7], the inhibitory effect 
of MTBP on p-Erk1/2 signaling is mainly caused by 
cytoplasmic MTBP, since a mutant MTBPNLS still retains 
the abilities to interact with IPO7 and inhibit nuclear 
translocation of p-Erk1/2. This finding is in concordance 
with our previous report where cytoplasmic MTBP binds 
to ACTN4 and inhibits ACTN4-mediated migration of 
cancer cells including HCC [7, 9]. Thus, the cytoplasmic 
MTBP appears to suppress cancer cell migration via 
multiple mechanisms.
Our unbiased luciferase-based pathway analyses 
show that MTBP might regulate other signaling pathways 
or their downstream targets apart from the Erk1/2-Elk-1 
signaling pathways. These include vitamin D receptor, 
MTF1, estrogen receptor, and HIF-1. Future studies are 
required to further validate these findings.
A compelling hypothesis is that MTBP may also 
regulate p-Erk nuclear import in multiple types of cancer 
cells. Since Erk1/2 activity is associated with disease 
progression and prognosis of HCC and other types of 
cancer [38-40], it would be vital to test this hypothesis. 
In conclusion, this study provides a new insight into HCC 
cell migration and metastasis through the regulation of the 
Erk1/2-Elk-1 pathway and helps identify a new therapeutic 
target for HCC metastasis.
MATERIALS AND METHODS
Cell lines
Huh7, PLC/PRF/5, and HepG2 cell lines were 
obtained from the KUMC liver center and maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% 
fetal bovine serum (FBS) and 1% penicillin-streptomycin 
in a humidified incubator at 37°C with 5% CO2. All cell 
lines were authenticated in the University of Arizona 
Genetics Core facility. Cell were treated with EGF at 
50 ng/ml for 15-30 min for examining RNA and protein 
expression, while 100 ng/ml of EGF was used for 12 hours 
of migration assays.
Plasmids and shRNAs
Coding regions for MTBP and ELK-1 were inserted 
into pCDH-CMV-MCS-EF1-Puro lentiviral vector 
(CD510B-1, SBI System Biosciences). FLAG-tagged 
MTBPNLS and ΔC-MTBP were also inserted into the 
pCDH-CMV-MCS-EF1-Puro vector, while FLAG-tagged 
F4-MTBP was inserted into pEF/FRT/V5-D-TOPO vector 
(Invitrogen, Grand Island, NY, USA).
The following are shRNA-encoding lentiviral vectors 
(cat#, target sequence) purchased from sigma: human Elk-1-
specific shRNA_1 (clone id-TRCNOT_042001_proof7450, 
CCGGCCCAAGAGTAACTCTCATTATCTCGAGATAA
TGAGAGTTACTCTTGGGTTTT), Erk1 (MAPK3, clone 
id- TRCNOT_042001_proof6150, CCGGCCTGAATTGTA
TCATCAACATCTCGAGATGTTGATGATACAATTCAG
GTTTT) and Erk2 (MAPK1, clone id- TRCN0000010040, 
CCGGCAAAGTTCGAGTAGCTATCAACTCGAGTTG
ATAGCTACTCGAACTTTGTTTTT). Lentiviral vector 
Oncotarget21440www.oncotarget.com
encoding a non-target control (RHS4346) and a human 
MTBP shRNA (V2LHS_253815) were purchased from GE 
Dharmacon RNAi Technologies (Lafayette, CO, USA).
Antibodies
For western blotting, the following antibodies 
were used: mouse monoclonal anti-MTBP (sc-137201, 
Santa Cruz), rabbit polyclonal anti-GAPDH (sc-27117, 
Santa Cruz), goat polyclonal anti-Lamin B (sc-6216, 
Santa Cruz), rabbit monoclonal anti-Elk-1 (# 9182, 
Cell Signaling), rabbit monoclonal anti-p-Elk-1 Ser383 
(# 9181, Cell Signaling), rabbit monoclonal anti-Erk1/2 
(# 4695, Cell Signaling), mouse monoclonal anti-p-
Erk1/2 (# 9106, Cell Signaling), rabbit monoclonal anti-
importin 7 (PAS5-25349, Thermo Scientific), mouse 
monoclonal anti-vinculin (10R-C105a, Fitzgerald, 
Acton, MA, USA). For co-immunoprecipitation studies; 
antibodies for mouse monoclonal anti-importin 7 (sc-
271701, Santa Cruz), goat polyclonal anti-MTBP (sc-
4717, Santa Cruz), rabbit monoclonal anti-p-Erk1/2 
Thr202/Tyr204 (#4370, Cell Signaling), and mouse 
monoclonal anti-FLAG (M2, Sigma) were used. For 
immunofluorescence and IHC studies, antibodies for goat 
polyclonal anti-MTBP (N-13, sc-47174, Santa Cruz) and 
rabbit monoclonal anti-p-Erk1/2 Thr202/Tyr204 (#4370, 
Cell Signaling) were used.
Immunofluorescence
Cells with or without treatment with EGF at 50 ng/ml 
for 30 min were plated onto poly-D-lysine/laminin-coated 
glass coverslips (BD Biosciences), fixed, and permeabilized 
with 4% formaldehyde in 100 mM PIPES (pH6.8), 10 
mM EGTA, 1 mM MgCl2, and 0.2% Triton-X 100 for 15 
min at room temperature. Following PBS washing, cells 
were blocked in 1% BSA in PBS plus 0.1% Tween 20 
(PBS-T) for 30 min and further incubated with primary 
antibodies overnight at 4°C. After PBS-T washing, cells 
were incubated with the appropriate secondary antibodies. 
Samples were mounted in the ProLong Gold Antifade 
Reagent (Invitrogen), and results were analyzed with a 
Nikon epifluorescence microscope (Nikon).
Signal pathway analysis
The Cignal Transduction 45-Pathway Reporter Array 
was purchased from SA Biosciences (Valencia, CA). Assays 
were performed according to the manufacturer’s instructions. 
Luciferase activity was measured using The Dual-Glo® 
Luciferase Assay System (Promega, Madison, WI) with 
BioTek Synergy H4 multifunctional plate reader (BioTek).
qRT-PCR
Total RNA from cell lines with or without treatment 
with EGF at 50 ng/ml for 15 min was isolated by using 
RNA Isolation Kit (Zymo research) and was reverse 
transcribed with Invitogen cDNA Synthesis Kit, starting 
with 1 μg total RNA from each sample, according to 
the manufacturer’s instructions. For detecting mRNA 
expression of Elk-1 downstream target genes, assays 
for EGR1 (Hs.PT.56a.40805543.g; IDT, Coralville, 
IA), c-fos (Hs.PT.56a.15540029; IDT), and PKCα (Hs.
PT.56a.15189405; IDT), and GAPDH (Hs 9999905-m1, 
Life Technologies) were used and analyzed using Applied 
Biosystems ViiA7 (Life Technologies).
Transwell migration assay
Migration assays were performed with 24-well 
transwell chambers (6.5mm diameter, 8 mm pore size, 
Corning). Cells (2×104 for PLC/PRF/5, 1×104 for Huh7, 
1×104 for HepG2) in 100 μl of 0.5% FBS-containing 
DMEM were seeded on the upper chamber, whereas in 
the lower chamber, 10% FBS-containing DMEM was 
added as a chemoattractant. EGF at 100 ng/ml was added 
into both the chambers. Cells were allowed for migrating 
through the membrane for 12 h. For the experiments with 
sorafenib (Santa Cruz; sc-220125), cells were pretreated 
with 5 μM of sorafenib for 12 hours, and sorafenib 
was continuously added into both the chambers during 
migration assays. The non-migrating cells were removed 
from the upper surface of the filters using cotton swabs 
and migrating cells to the lower surface were stained with 
Diff-Quik Stain Set (Dade Behring). Stained cells in the 
entire fields were counted under an inverted microscope.
Co-immunoprecipitation
Cells were lysed with IP lysis buffer (Sigma) 
containing protease inhibitor cocktail (Roche Applied 
Science). Approximately 200 μg of whole cell lysates 
were incubated with protein-specific antibodies overnight 
at 4°C, followed by precipitation of the antibody-protein 
complex using protein A/G plus-agarose (Santa Cruz 
Biotechnology). 10% of the total amount of protein 
lysate (~20 μg) was used for input. In each experiment, 
an isotype negative control was used. After washing with 
IP lysis buffer, precipitates were analyzed by western 
blotting.
Immunohistochemistry (IHC)
Liver cancer tissue array was purchased from US 
Biomax (LV1221) containing liver carcinoma and non-
tumor liver tissues. Another 5 non-tumor liver tissues were 
obtained from the KUMC Liver Center to increase the 
number of controls. Tissue sections were deparaffinized 
in xylene and rehydrated through a series of graded 
alcohols. Slides were washed with PBS, and endogenous 
peroxidases were blocked with 1.5% hydrogen peroxide 
in PBS for 20 min at 25°C. After three 5 min washes with 
PBS, slides were incubated in blocking solution (PBS 
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with 0.1% Triton X-100, 3% bovine serum albumin) with 
5% normal donkey serum for 10 min at 25°C. Following 
antigen retrieval with sodium citrate buffer (10mM sodium 
citrate, pH 6.0) for 20 min, IHC was performed using the 
Vector R.T.U. Vectastain Kit (PK-7800). The sections 
were incubated with primary antibodies overnight at 4°C, 
washed with PBS, and were incubated with biotinylated 
secondary antibodies at room temperature for 30 min. 
Vector ImmPact DAB Peroxidase Substrate Kit (Vector 
Labs, Cat #SK-4105) was used for color development, 
followed by hematoxylin counterstaining. All stained 
sections were blindly evaluated by three independent 
investigators. Expression scores were determined based 
on intensity and extensity by assessing the whole tumor 
section. Each sample was scored on a scale of 0–3 for 
extensity with 0 corresponding to less than 25% of positive 
tumor cells; 1 for 26–50%; 2 for 51–75%; and 3 for 76–
100% and the intensity of immunostaining was graded 
as 0 (negative staining), 1 (weakly positive staining), 2 
(moderately positive staining), and 3 (strongly positive 
staining). The immunoreactive expression score of each 
section was calculated by the sum of these two parameters 
and presented as a score ranging between 0-6 as previously 
described [41]. Three independent investigators evaluated 
all stained sections. Final score was taken as an average 
from their individual score.
Statistical analysis
Experiments were performed independently at least 
three times with values expressed as mean ± standard 
deviation (S.D.). For IHC analyses, a Kruskal-Wallis 
test was used to compare MTBP levels across non-
tumor liver, primary HCC and metastatic HCC tissues. 
Pairwise comparisons were conducted with 1-tailed 
Mann-Whitney tests, using a nominal significance level 
of 0.05 and considering p-values <0.017 as significant 
for a Bonferroni correction. Association between p-Erk 
localization (C>N vs C≤N) and MTBP expression score 
(<3 vs ≥3) was investigated with a Fisher’s exact test in a 
bivariate analysis. To control the potentially confounding 
effect of tumor location, an exact logistic regression of 
p-Erk localization was used; the dependent variable of 
the model was p-Erk localization, while the independent 
variables were MTBP categorization and tumor location. 
All other experimental results were analyzed using 
Student’s t-test. In these analyses, a p-value of 0.05 
or lower was considered to be statistically significant. 
Statistical analyses were performed with Graph Pad 
Prism software (San Diego, CA) and Stata (StataCorp LP, 
College Station, TX).
Abbreviations
MDM2, mouse double minute 2 homolog; MTBP, 
MDM2 Binding Protein; ACTN4, α-actinin 4; Erk, 
extracellular signal-regulated kinase; MAP, mitogen-
activated protein kinase; RT-PCR, reverse transcriptase-
polymerase chain reaction; PBS, phosphate buffered 
saline; RIPA, radio immunoprecipitation assay; DMSO, 
dimethyl sulfoxide; EGR-1, early growth response protein 
1; PKCα, protein kinase C alpha.
Author contributions
The authors contributed in the following way: 
AR, SVI, CW, TL, OWT, TI: performed experiments; 
AR, FJD, AD, SAW, YA, TIz, TI: designed the research 
and analyzed the data; AR, SVI, CW, AD, YA, TL, FJD, 
TIz, TI: wrote the manuscript. All authors reviewed and 
approved the manuscript.
ACKNOWLEDGMENTS
We thank Danny R. Welch, Alejandro Parrales, 
Satomi Yamamoto, Elizabeth Thoenen, and Liver Center 
at KUMC for technical assistance, helpful discussion, 
providing human tissues, and editing the manuscript.
CONFLICTS OF INTEREST
No potential conflicts of interest were disclosed.
FUNDING
This project is supported by NIH R01-CA174735 
(T.I.), P30-CA168524 (R.A.J.), and Children’s Mercy Big 
Slick KC grants.
REFERENCES
1. Fidler IJ, Kripke ML. The challenge of targeting metastasis. 
Cancer Metastasis Rev. 2015; 34:635-641.
2. Talmadge JE, Fidler IJ. AACR centennial series: the biology 
of cancer metastasis: historical perspective. Cancer Res. 
2010; 70:5649-5669.
3. Bruix J, Sherman M; Practice Guidelines Committee, 
American Association for the Study of Liver Diseases. 
Management of hepatocellular carcinoma. Hepatology. 
2005; 42:1208-1236.
4. Si MS, Amersi F, Golish SR, Ortiz JA, Zaky J, Finklestein 
D, Busuttil RW, Imagawa DK. Prevalence of metastases 
in hepatocellular carcinoma: risk factors and impact on 
survival. Am Surg. 2003; 69:879-885.
5. Boyd MT, Vlatkovic N, Haines DS. A novel cellular protein 
(MTBP) binds to MDM2 and induces a G1 arrest that is 
suppressed by MDM2. J Biol Chem. 2000; 275:31883-31890.
6. Iwakuma T, Agarwal N. MDM2 binding protein, a novel 
metastasis suppressor. Cancer Metastasis Rev. 2012; 
31:633-640.
Oncotarget21442www.oncotarget.com
7. Agarwal N, Adhikari AS, Iyer SV, Hekmatdoost K, Welch 
DR, Iwakuma T. MTBP suppresses cell migration and 
filopodia formation by inhibiting ACTN4. Oncogene. 2013; 
32:462-470.
8. Vlatkovic N, El-Fert A, Devling T, Ray-Sinha A, Gore DM, 
Rubbi CP, Dodson A, Jones AS, Helliwell TR, Jones TM, 
Boyd MT. Loss of MTBP expression is associated with 
reduced survival in a biomarker-defined subset of patients 
with squamous cell carcinoma of the head and neck. Cancer. 
2011; 117:2939-2950.
9. Bi Q, Ranjan A, Fan R, Agarwal N, Welch DR, Weinman 
SA, Ding J, Iwakuma T. MTBP inhibits migration 
and metastasis of hepatocellular carcinoma. Clin Exp 
Metastasis. 2015; 32:301-311.
10. Odvody J, Vincent T, Arrate MP, Grieb B, Wang S, Garriga 
J, Lozano G, Iwakuma T, Haines DS, Eischen CM. A 
deficiency in Mdm2 binding protein inhibits Myc-induced 
B-cell proliferation and lymphomagenesis. Oncogene. 
2010; 29:3287-3296.
11. Grieb BC, Gramling MW, Arrate MP, Chen X, Beauparlant 
SL, Haines DS, Xiao H, Eischen CM. Oncogenic protein 
MTBP interacts with MYC to promote tumorigenesis. 
Cancer Res. 2014; 74:3591-3602.
12. Grieb BC, Chen X, Eischen CM. MTBP is overexpressed 
in triple-negative breast cancer and contributes to its growth 
and survival. Mol Cancer Res. 2014; 12:1216-1224.
13. Agarwal N, Tochigi Y, Adhikari AS, Cui S, Cui Y, Iwakuma 
T. MTBP plays a crucial role in mitotic progression 
and chromosome segregation. Cell Death Differ. 2011; 
18:1208-1219.
14. Boos D, Yekezare M, Diffley JF. Identification of a 
heteromeric complex that promotes DNA replication origin 
firing in human cells. Science. 2013; 340:981-984.
15. Todisco A, Takeuchi Y, Yamada J, Sadoshima JI, Yamada T. 
Molecular mechanisms for somatostatin inhibition of c-fos 
gene expression. Am J Physiol. 1997; 272:G721-726.
16. Gallo A, Cuozzo C, Esposito I, Maggiolini M, Bonofiglio 
D, Vivacqua A, Garramone M, Weiss C, Bohmann D, 
Musti AM. Menin uncouples Elk-1, JunD and c-Jun 
phosphorylation from MAP kinase activation. Oncogene. 
2002; 21:6434-6445.
17. Brady M, Vlatkovic N, Boyd MT. Regulation of p53 
and MDM2 activity by MTBP. Mol Cell Biol. 2005; 
25:545-553.
18. Ying TH, Hsieh YH, Hsieh YS, Liu JY. Antisense 
oligonucleotide Elk-1 suppresses the tumorigenicity of 
human hepatocellular carcinoma cells. Cell Biol Int. 2008; 
32:210-216.
19. Hayashi J, Aoki H, Kajino K, Moriyama M, Arakawa 
Y, Hino O. Hepatitis C virus core protein activates 
the MAPK/ERK cascade synergistically with tumor 
promoter TPA, but not with epidermal growth factor or 
transforming growth factor alpha. Hepatology. 2000; 
32:958-961.
20. Kasza A. Signal-dependent Elk-1 target genes involved in 
transcript processing and cell migration. Biochim Biophys 
Acta. 2013; 1829:1026-1033.
21. Odrowaz Z, Sharrocks AD. ELK1 uses different DNA 
binding modes to regulate functionally distinct classes of 
target genes. PLoS Genet. 2012; 8:e1002694.
22. Flores K, Seger R. Stimulated nuclear import by beta-like 
importins. F1000Prime Rep. 2013; 5:41.
23. Casar B, Sanz-Moreno V, Yazicioglu MN, Rodriguez 
J, Berciano MT, Lafarga M, Cobb MH, Crespo P. Mxi2 
promotes stimulus-independent ERK nuclear translocation. 
EMBO J. 2007; 26:635-646.
24. Lorenzen JA, Baker SE, Denhez F, Melnick MB, Brower 
DL, Perkins LA. Nuclear import of activated D-ERK by 
DIM-7, an importin family member encoded by the gene 
moleskin. Development. 2001; 128:1403-1414.
25. Chuderland D, Konson A, Seger R. Identification and 
characterization of a general nuclear translocation signal in 
signaling proteins. Mol Cell. 2008; 31:850-861.
26. Ha TY, Hwang S, Moon KM, Won YJ, Song GW, Kim N, 
Tak E, Ryoo BY, Hong HN. Sorafenib inhibits migration 
and invasion of hepatocellular carcinoma cells through 
suppression of matrix metalloproteinase expression. 
Anticancer Res. 2015; 35:1967-1976.
27. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, 
Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner 
A, Schwartz M, Porta C, Zeuzem S, et al. Sorafenib in 
advanced hepatocellular carcinoma. N Engl J Med. 2008; 
359:378-390.
28. Zhao J, Dong QZ, Zhong F, Cai LL, Qin ZY, Liu Y, Lin CZ, 
Qin LX, He FC. NMI promotes hepatocellular carcinoma 
progression via BDKRB2 and MAPK/ERK pathway. 
Oncotarget. 2017; 8:12174-12185. https://doi.org/10.18632/
oncotarget.14556.
29. Sun W, Zhang Z, Wang J, Shang R, Zhou L, Wang X, 
Duan J, Ruan B, Gao Y, Dai B, Qu S, Liu W, Ding R, et al. 
MicroRNA-150 suppresses cell proliferation and metastasis 
in hepatocellular carcinoma by inhibiting the GAB1-
ERK axis. Oncotarget. 2016; 7:11595-11608. https://doi.
org/10.18632/oncotarget.7292.
30. Lu JT, Zhao WD, He W, Wei W. Hedgehog signaling 
pathway mediates invasion and metastasis of hepatocellular 
carcinoma via ERK pathway. Acta Pharmacol Sin. 2012; 
33:691-700.
31. Wortzel I, Seger R. The ERK cascade: distinct functions 
within various subcellular organelles. Genes Cancer. 2011; 
2:195-209. https://doi.org/10.1177/1947601911407328.
32. Hsieh YH, Wu TT, Tsai JH, Huang CY, Hsieh YS, Liu JY. 
PKCalpha expression regulated by Elk-1 and MZF-1 in 
human HCC cells. Biochem Biophys Res Commun. 2006; 
339:217-225.
33. Hipskind RA, Rao VN, Mueller CG, Reddy ES, Nordheim 
A. Ets-related protein Elk-1 is homologous to the c-fos 
regulatory factor p62TCF. Nature. 1991; 354:531-534.
Oncotarget21443www.oncotarget.com
34. Robinson L, Panayiotakis A, Papas TS, Kola I, Seth A. ETS 
target genes: identification of EGR1 as a target by RNA 
differential display and whole genome PCR techniques. 
Proc Natl Acad Sci U S A. 1997; 94:7170-7175.
35. Yue CH, Huang CY, Tsai JH, Hsu CW, Hsieh YH, 
Lin H, Liu JY. MZF-1/Elk-1 complex binds to protein 
kinase calpha promoter and is involved in hepatocellular 
carcinoma. PLoS One. 2015; 10:e0127420.
36. Fan Q, He M, Deng X, Wu WK, Zhao L, Tang J, Wen G, Sun 
X, Liu Y. Derepression of c-Fos caused by microRNA-139 
down-regulation contributes to the metastasis of human 
hepatocellular carcinoma. Cell Biochem Funct. 2013; 
31:319-324.
37. Wang L, Sun H, Wang X, Hou N, Zhao L, Tong D, He 
K, Yang Y, Song T, Yang J, Huang C. EGR1 mediates 
miR-203a suppress the hepatocellular carcinoma cells 
progression by targeting HOXD3 through EGFR signaling 
pathway. Oncotarget. 2016; 7:45302-45316. https://doi.
org/10.18632/oncotarget.9605.
38. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, 
Malago M, Steveling K, Reis H, Cicinnati VR, Schmid 
KW, Baba HA. Activation of the ERK and AKT signalling 
pathway predicts poor prognosis in hepatocellular 
carcinoma and ERK activation in cancer tissue is associated 
with hepatitis C virus infection. J Hepatol. 2008; 48:83-90.
39. Li GD, Cai ZD, Zhang YQ, Gong HY, Tang H, Zhang 
QL. [Gene profiling of MAPK pathway in human 
osteosarcoma]. [Article in Chinese]. Zhonghua Zhong Liu 
Za Zhi. 2009; 31:340-345.
40. Won JK, Yang HW, Shin SY, Lee JH, Heo WD, Cho KH. 
The crossregulation between ERK and PI3K signaling 
pathways determines the tumoricidal efficacy of MEK 
inhibitor. J Mol Cell Biol. 2012; 4:153-163.
41. Gao J, Chen C, Hong L, Wang J, Du Y, Song J, Shao X, 
Zhang J, Han H, Liu J, Fan D. Expression of Jagged1 
and its association with hepatitis B virus X protein in 
hepatocellular carcinoma. Biochem Biophys Res Commun. 
2007; 356:341-347.
